Chief Scientific Officer, Numinus Wellness. Adjunct Professor, University of Utah.
Numinus Wellness
Salt Lake City, Utah
Dr. Paul Thielking is board certified in Psychiatry and in Hospice and Palliative Medicine and serves as the Chief Scientific Officer of Numinus, a leading mental health organization focused on psychedelic research and on developing clinical models of care that will help make psychedelic treatments accessible to those who need them most. Prior to his current role with Numinus, Dr. Thielking was an Associate Professor at the University of Utah where he created the University of Utah’s Huntsman Cancer Institute (HCI) Psycho-oncology program. In his role at HCI, Dr. Thielking became focused in recent years on developing a new psychedelic assisted therapy and research program. One of his major clinical achievements at the HCI included the successful integration of Ketamine Assisted Psychotherapy (KAP) within an outpatient oncology clinic. In addition to clinical program development, Dr Thielking led exciting new research initiatives including a pilot study of group administered psilocybin treatment for cancer patients with depression. Dr. Thielking’s experience in the creation of psychedelic clinical and research protocols, along with his expertise in group interventions that bridge Psychiatry and Palliative Care, place him in a unique position on the frontier of the emerging field of psychedelic medicine.
Virtual
Disclosure information not submitted.
